How many drugs treat Candidiasis of mouth?

Drug Landscape tracks 7 marketed treatments for Candidiasis of mouth (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/candidiasis-of-mouth.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Candidiasis of mouth — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Candidiasis of mouth (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Candidiasis of mouth, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Diflucan	fluconazole	Pfizer Inc.	Azole Antifungal [EPC]	Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase	1990-01-29
Nizoral	ketoconazole	Johnson & Johnson (Janssen)	Azole Antifungal [EPC]	Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1	1981-06-26
Lotrimin	clotrimazole	Bayer AG	Azole Antifungal [EPC]	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1975-01-01
Monistat	miconazole	Johnson & Johnson (Janssen)	Imidazole antifungal	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1974-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Mycostatin	nystatin	Generic (originally Squibb)	Polyene Antifungal [EPC]	Ergosterol (fungal cell membrane)	1954-01-01
Fluconazol	Fluconazol	Azienda Sanitaria-Universitaria Integrata di Udine		Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Johnson & Johnson (Janssen) · 2 drugs in Candidiasis of mouth
Astellas Pharma · 1 drug in Candidiasis of mouth
Azienda Sanitaria-Universitaria Integrata di Udine · 1 drug in Candidiasis of mouth
Bayer AG · 1 drug in Candidiasis of mouth
Generic (originally Squibb) · 1 drug in Candidiasis of mouth
Pfizer Inc. · 1 drug in Candidiasis of mouth

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Candidiasis of mouth:

Cite this brief

Drug Landscape (2026). Candidiasis of mouth — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/candidiasis-of-mouth. Accessed 2026-06-10.

Candidiasis of mouth full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing